Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 9;8(13):3544-3548.
doi: 10.1182/bloodadvances.2024013243.

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

Adam J Lamble  1 , Liora M Schultz  2 , Khanh Nguyen  2 , Emily M Hsieh  3 , Kevin McNerney  4 , Rayne H Rouce  5 , Rebecca A Gardner  6 , Sara Ghorashian  7 , Nirali N Shah  8 , Shannon L Maude  9
Affiliations

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

Adam J Lamble et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.N.S. receives research funding from Lentigen, Vor Bio, and CARGO Therapeutics, and has attended advisory board meetings (no honoraria) for Vor Bio, ImmunoACT, and Sobi. S.G. reports honoraria from Novartis; patents with University College London Business Ltd; and trial steering committee participation for Autolus. L.M.S. reports advisory board fees from Novartis Pharmaceuticals and CARGO Therapeutics. R.A.G. receives royalty payments related to patents from Juno Therapeutics, unrelated to this work. S.L.M. has received clinical trial support from and has served on advisory and study steering committees for Novartis and Wugen, and has a patent pending and licensed to Novartis Pharmaceuticals without royalty for PCT/US2017/044425: “Combination Therapies of Chimeric Antigen Receptors and PD-1 Inhibitors.” E.M.H. consults for Novartis. R.H.R. has served as a consultant for Pfizer; received honoraria from Novartis; and reports research support from Tessa Therapeutics. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Postinfusion T-cell malignancy results from global survey of centers treating CAYAs with CAR T cells. B-NHL, B-cell non-Hodgkin lymphoma; GBM, glioblastoma multiforme.
See this image and copyright information in PMC

References

    1. Micklethwaite KP, Gowrishankar K, Gloss BS, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138(16):1391–1405. - PMC - PubMed
    1. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584–586. - PubMed
    1. Levine BL, Pasquini MC, Connolly JE, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338–341. - PMC - PubMed
    1. Elsallab M, Ellithi M, Lunning MA, et al. Second primary malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS) Blood. 2024;143(20):2099–2105. - PubMed
    1. Harrison SJ, Nguyen T, Rahman M, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 2023;142(suppl 1):6939.

Publication types

Substances